< 1 minute read
Oct. 6, 2021

ZN-c3: A Selective Wee1 Kinase Inhibitor

ZN-c3

selective oral Wee1 kinase inh. (300 mg QD) Ph. II candidate for uterine serous carcinoma from literature starting point Journal of Medicinal Chemistry Zentalis Pharmaceuticals, San Diego, CA, USA

twitterlinkedinprintemail